Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IIIb, Multicentre, Open-label, Single-arm, Study to Assess the Efficacy and Safety of Lanreotide Autogel 120 mg Administered Every 28 Days as Primary Medical Treatment in Acromegalic Patients With Macroadenoma

NCT00690898 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT00690898
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00690898 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IIIb, Multicentre, Open-label, Single-arm, Study to Assess the Efficacy and Safety of Lanreotide Autogel 120 mg Administered Every 28 Days as Primary Medical Treatment in Acromegalic Patients With Macroadenoma
Lead sponsor
Ipsen
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2008
Completion date
February 29, 2012
Enrollment
108 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

acromegaly